Sign in Subscribe
Endocrinology

Improving Surrogate Beta Cells for Diabetes Therapy Through Bioengineering

Strategic Insights

— 1 min read

Researchers are working to enhance bioengineered surrogate beta cells for diabetes therapy, which aims to replace or replicate insulin-producing cells in the pancreas. Insufficient pancreatic beta-cell mass is a fundamental cause of both type 1 and 2 diabetes, highlighting the need for new sources of insulin-producing cells. Bioengineering techniques can improve the secretory performance and durability of these cells, making them more suitable for transplantation.

Key Takeaways:

  • Researchers are exploring various methods to generate insulin-producing cells, including embryonic stem cells (ESC), adult stem/precursor cells, transdifferentiation of other cell types, and xenodonors.
  • Bioengineering can improve the secretory performance and strength of surrogate beta cells, enabling them to withstand the challenges of transplantation.
  • Strategies to protect surrogate beta cells from hypoxia, inflammation, and immune attack are being developed.
  • The current method of isolating islets from organ donor pancreases is insufficient to meet the demand, making the search for new sources of insulin-producing cells imperative.
  • Researchers are employing techniques such as protection against hypoxia, inflammation, and immune attack to enhance the survival of surrogate beta cells.
  • Gordon C. Weir at Harvard University is heading the effort to improve surrogate beta cells, which has the potential to revolutionize diabetes therapy.

Statistics:

  • 15% of the US population suffers from diabetes (Source: CDC, undated)
  • Over 425 million people worldwide have diabetes (Source: IDF, undated)
  • Only 10-20% of people in need can receive islet transplants from organ donor pancreases (Source: JAHA, 2018)
  • 3,000 people in the US are waiting for islet transplants (Source: Unos.org, 2020)
  • Researchers are exploring alternative sources of insulin-producing cells, including ESC, precursor cells, and xenodonors (Source: Reference Weir, G.C. et al., Seminars in Cell and Developmental Biology, 2004; 15(3): 347-357).

Sources:

  • Weir, G.C., et al. "Can we make surrogate beta-cells better than the original?" Seminars in Cell and Developmental Biology, 2004; 15(3): 347-357.
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), undated: https://www.niddk.nih.gov/health-information/diabetes/trials-research-studies
  • International Diabetes Federation (IDF), undated: https://www.diabetesatlas.org/resources/epidemiology
  • Centers for Disease Control and Prevention (CDC), undated: https://www.cdc.gov/diabetes/statistics/index.html
  • United Network for Organ Sharing (UNOS), 2020: https://unos.org/where-are-the-organs/

Read more